SCHEMBL1489833

SCHEMBL1489833

Cc1cc(C)n(-c2cc(NC(=O)C(C)N3CCN(C)CC3)nc(-c3ccco3)n2)n1

nearest known ligand 0.72

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 20/20 0.72
ADORA1 P30542 18/20 0.72
KCNH2 Q12809 4/20 0.54
ADORA3 P0DMS8 2/20 0.48
ADORA2B P29275 2/20 0.48
CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5016115 0.86 ADORA2A (0.66) ADORA2AADORA1KCNH2ADORA3ADORA2B
SCHEMBL1489504 0.83 ADORA2A (1.00) ADORA2AADORA1KCNH2ADORA3ADORA2B
SCHEMBL5022353 0.82 ADORA2A (0.70) ADORA2AADORA1KCNH2ADORA3ADORA2B
SCHEMBL5022395 0.80 ADORA2A (0.67) ADORA2AADORA1KCNH2ADORA3ADORA2B
SCHEMBL1489143 0.79 ADORA2A (0.74) ADORA2AADORA1KCNH2ADORA3ADORA2B
SCHEMBL8288702 0.79 ADORA2A (0.74) ADORA2AADORA1KCNH2ADORA3ADORA2B
SCHEMBL5016129 0.79 ADORA2A (0.66) ADORA2AADORA1KCNH2ADORA3ADORA2B
SCHEMBL5022235 0.79 ADORA2A (0.57) ADORA2AADORA1KCNH2ADORA3ADORA2B
SCHEMBL5023157 0.77 ADORA2A (0.71) ADORA2AADORA1KCNH2ADORA3ADORA2B
SCHEMBL5022559 0.77 ADORA2A (0.70) ADORA2AADORA1KCNH2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1888565-B1 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL SA (ES) 2011-03-23 EP claimed
US-20080275064-A1 Substituted Pyrimidines as Adenosine Receptor Antagonists ALMIRALL, S.A. (ES) 2008-11-06 US claimed
EP-1888565-A2 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS NEUROCRINE BIOSCIENCES, INC. (US) 2008-02-20 EP claimed
WO-2006110884-A2 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS NEUROCRINE BIOSCIENCES, INC. (US) 2006-10-19 WO claimed
EP-1888565-B1 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL SA (ES) 2011-03-23 EP disclosed
US-20080275064-A1 Substituted Pyrimidines as Adenosine Receptor Antagonists ALMIRALL, S.A. (ES) 2008-11-06 US disclosed
EP-1888565-A2 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS NEUROCRINE BIOSCIENCES, INC. (US) 2008-02-20 EP disclosed
WO-2006110884-A2 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS NEUROCRINE BIOSCIENCES, INC. (US) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275064-A1 Substituted Pyrimidines as Adenosine Receptor Antagonists ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885KCNH2 1242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.